What is HC Wainwright’s Forecast for PVLA FY2027 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Investment analysts at HC Wainwright cut their FY2027 earnings per share (EPS) estimates for Palvella Therapeutics in a research note issued on Monday, December 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($3.65) per share for the year, down from their previous forecast of ($3.62). HC Wainwright has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2028 earnings at ($2.42) EPS and FY2029 earnings at $0.25 EPS.

A number of other equities analysts have also recently commented on the stock. Stifel Nicolaus lifted their target price on shares of Palvella Therapeutics from $87.00 to $145.00 and gave the company a “buy” rating in a report on Monday, November 24th. Canaccord Genuity Group raised their price objective on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday. Truist Financial raised their price target on Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a report on Monday. Finally, BTIG Research boosted their price target on Palvella Therapeutics from $167.00 to $192.00 and gave the company a “buy” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $155.60.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $92.01 on Thursday. The company has a market capitalization of $1.09 billion, a P/E ratio of -34.98 and a beta of -0.20. Palvella Therapeutics has a fifty-two week low of $11.17 and a fifty-two week high of $112.00. The stock has a 50-day simple moving average of $84.68 and a 200-day simple moving average of $56.38.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18).

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors have recently added to or reduced their stakes in PVLA. Archer Investment Corp acquired a new position in Palvella Therapeutics during the 3rd quarter worth approximately $28,000. Bank of America Corp DE boosted its stake in shares of Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after buying an additional 515 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics during the third quarter worth $36,000. JPMorgan Chase & Co. raised its position in Palvella Therapeutics by 33.7% in the third quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock worth $272,000 after acquiring an additional 1,093 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in Palvella Therapeutics in the second quarter worth $37,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $86.23, for a total transaction of $370,961.46. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.50% of the stock is currently owned by company insiders.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.